Stability Study of Vaccines
Stability Study of Vaccines
Stability is the ability of a vaccine to retain its chemical, physical, microbiological and biological
properties within specified limits throughout its shelf-life.
Pharmaceutical form
Lyophylized versus liquid
Storage
Frozen versus refrigerator
U.L.: The highest dose at which we are comfortable, based on the clinical data, that the vaccine
is going to be safe. This is normally a specification.
Dose
Stability profile
Analytical assay variability
Confidence limits
Two models
Compliance model – Substantially all potency measurements should exceed some predefined
quantity.
Often, the mean potency from clinical trials is used to set this minimum specification
This is very difficult (perhaps impossible) to reliably implements in original clinical tests were
performed based on an understanding of mean potency, not on an understanding of “all potency
measurements.”
Estimation model – The mean potency of substantially all vaccine lots should be at a level that is
not less than the mean potency of vaccine lots shown to be effective in clinical trials.
Compliance model
Shelf life is set arbitrarily depending on the luck associated with each individual assay at each
time point, and based on the starting potencies of lots on test.
Release potency must be high enough to prevent test results that fall below L.L. due to assay
variability, from requiring an unacceptably short shelf life, or from subsequently failing stability
monitoring studies.
Estimation method
Statistical methods (when appropriate, a regression line analysis) also can be used to estimate
lower bounds on the mean potency estimate at end-expiry for any given release potency, thus
allowing estimation of shelf life. Modeling can be performed after three or more stability time
points have been obtained.
Development-what do we need to know about stability?
What are the kinetics of decay?
What are the degradation products?
Are there stability-influencing factors that should also be controlled?
Do we have sufficient knowledge of the stability of intermediates?
Are the assays adequate?
Are potency assays stability-indicating?
Are potency assays precise enough to support product development?
Do we have a sufficient understanding of material tested in clinical trials?
Do we have a sufficient understanding of product performance at potency ranges likely to be
encountered post-licensure?
TYPES OF STABILITY
Real Time Stability: Long term stability under recommended storage conditions for the shelf life
proposed for the product.
Accelerated Testing: Studies under exaggerated storage conditions.
Stress studies: More severe conditions than those used for accelerated studies.
Real time / real condition stability studies
Studies on the physical, chemical, biological, biopharmaceutical and microbiological
characteristics of a vaccine, during and up to the expected shelf-life and storage periods of
samples under expected handling and storage conditions.
Stress testing
Studies performed to determine the impact of extreme environmental factors such as light and
extreme temperature (may include oxidizing agents, freeze thaw, pH). These studies are not
usually performed as part of a stability program, but are used instead to establish protective
packaging and container conditions, and to support exclusionary labeling.
TEMPERATURES
Real Time: Storage Temperature of the product e.g. 2-8°C for Tetanus Vaccine
Accelerated: 15±2°C higher than the maximum temperature of storage at real time storage of the
product e.g. 25 ± 2°C
Stress: +10°C ± 2°C than the accelerated temperature e.g.35 ± 2°C
Real Time: 2-8°C for 4 years (for 3 years expiry)
0, 3M, 6M, 9M, 12M, 18M, 24M, 36M & 48M
Accelerated Temperature: 20-25°C for 6 months
0, 1M, 2M, 3M & 6 Months
Stress Study: 35°C for 1-2 months
0, 1, 2, 3, 4, 5, 6 ,7 & 8 weeks
SAMPLE
DRUG SUBSTANCES:
INTERMEDIATE PRODUCT: ACTIVE RAW MATERIAL
FORMULATED BULK: FINAL BULK
DRUG PRODUCT:
FINISHED PRODUCT: FINAL LOT
DESIGN
Bracketing: Extremes of certain design factors, e.g.
Strength: 10 ug, 25ug, 100 ug
Package size: 1 dose, 5 dose, 10 dose
Matrixing: A selected subset of the total number of the possible samples for all factors is tested
at specified time and at a subsequent time another subset of samples for all factors is tested.
Stability indicating parameters
Choice of parameters to be tested:
Depends of the;
Product characteristics
Link between vaccine quality and efficacy or safety
as demonstrated in clinical trials – ideal case.
Potency, antigen content, appearance, pH, completeness of adsorption, adjuvant content;
physicochemical, properties, etc.
New vaccines: parameters to be identified during the product development
ACCEPTANCE CRITERIA
In general, significant change is defined as:
5% change in assay from the initial value or failure to meet the acceptance criteria by biological
or immunological parameters or as applicable for the specification of the product.
Any degradation product (impurity) exceeding its acceptance criteria
ACCEPTANCE CRITERIA
Failure to meet the acceptance criteria for physical and chemical parameters
Failure to meet the acceptance criteria for dissolution for stipulated dosages.
Cumulative age of an antigen in the final product
Reported as a major issue in practice
Final product should be stable during the whole period of shelf-life irrespective of the age of its
intermediate products
Data should be collected on an ongoing basis – usually not available before approval of storage
periods and shelf-life
Accelerated stability studies - to demonstrate that an aged intermediate did not affect stability of
the final product
Thermal stability testing – lot release
An indicator of consistency of production of the real time.
TS is a shelf-life specification in current WHO vaccine specific recommendations
Live attenuated vaccines – OPV, MMR, YF
For other vaccines: consider relevance of the rate of change for safety and efficacy
Thermal stability testing
Stability of a vaccine after exposure to a temperature, higher than those recommended for
storage, for a specified period of time, often expressed in terms of change in potency.
Example:
OPV: potency shall not be reduced more than 0.5 log CCID50
Stability of a vaccine in the case of known ‘’short time excursions’’ outside the labeled storage
conditions
Possibility of temperature excursion during transportation
Take the samples out of cold chain (2-8°C) and put them at 25°C for a short period such as 1 ay
or 8 hours and then return them back to the normal cols chain condition.
Samples can be taken out of the cold chain at the first period and/or the middle period and/or the
last period of shelf life after released
The release specification may be calculated by adding the correction factor from this stability
study.
Stability study to support selection of VVM
A vaccine vial monitor, or VVM, is a circular indicator, printed directly on the vaccine vial label
or affixed to the top of the vial or ampoule. The inner square of the VVM is made of heat-
sensitive material that is initially light in color and becomes darker when exposed to heat over
time.